Follow Us
https://www.thebody.com/author/coverage-provided-donald-l-kaminsky

Latest by Donald L. Kaminsky, M.D.

Promo Image
News

BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers

This study is one of several posters on new protease inhibitors that are under development. In particular, BMS-232632 shows an EC50 value ranging from 25 nM. This is a report of a single dose study and some preliminary results from ongoing multiple d...

Promo Image

The Long Term Response to Combination Therapy Commenced Early in HIV Infection: 3 Year Follow-Up: What's Happened Since Vancouver?

This paper is interesting because I think it is a definite rebuttal to those who have expressed real discouragement that triple therapy did not prove to be as effective as first thought. I think it always has to be kept in mind that what is now avail...

Promo Image
News

Avascular Necrosis in HIV-Infected Patients: A Potential Link to Protease Inhibitors

This study was of particular interest to me because I have had three patients in my own practice who developed this particular complication in the last 18 months. Prior to that I had never seen this and, talking to other HIV physicians, this was a ra...

Promo Image
News

Immunologic Reconstitution After 12 Months of Antiretroviral Therapy in Very Early Stages of Chronic HIV-1 Infection

In this first study from Barcelona, the authors looked at the effectiveness of four different antiretroviral combinations to reduce viral load, to correct T cell subset abnormalities and to restore immune function in asymptomatic HIV-1 infected patie...

Promo Image
News

Efficacy of Efavirenz (Sustiva) Concerning Regimens in Patients With Baseline Plasma HIV-1 RNA Viral Load Exceeding 100,000 copies/mL

Sustiva is a once-daily non-nucleoside reverse transcriptase inhibitor (NNRTI) which has demonstrated efficacy when used combination with either a protease inhibitor, NRTI or both in ARV naïve NRTI extreme patients. The antiretroviral activity of NNR...

Promo Image
News

The Multiple Nucleoside Analogue Resistance Mutations Confer Cross-Resistance to Abacavir

In this collaborative European study the authors began with the observation that the mutation Q151M, together with other mutations that code on 62, 68, 75, 77 and 116 of the HIV I RT gene response for high level resistance against the NRTI's. Abacavi...

Promo Image
News

Viral and Immunologic Examination of HIV-I-Infected Persistently Seronegative Persons

In this study the authors observed that in detecting HIV I infection the modalities used were based on serological testing for antibodies. There are nine commercial licensed EIA type kits and confirmation is usually done using Western blot or IFA. Th...